July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Efficacy and safety of diquafosol ophthalmic solution for soft contact lens-related dry eye
Author Affiliations & Notes
  • Hiroki Asano
    Ophthalmology, Namegata District Medical Center, Namegata, Ibaraki, Japan
  • Tomohiro Ogami
    Ophthalmology, Ibaraki Seinan Medical Center Hospital, Sakai-machi, Ibaraki, Japan
  • Aya Iguchi
    Ophthalmology, Namegata District Medical Center, Namegata, Ibaraki, Japan
  • Maki Sano
    Ophthalmology, Ibaraki Seinan Medical Center Hospital, Sakai-machi, Ibaraki, Japan
  • Yoshiaki Yamada
    Global Research and Development, Santen Pharmaceutical Co., Ltd., Osaka, Osaka, Japan
  • Takahiro Hiraoka
    Ophthalmology, Tsukuba Univ., Tsukuba, Ibaraki, Japan
  • Tetsuro Oshika
    Ophthalmology, Tsukuba Univ., Tsukuba, Ibaraki, Japan
  • Footnotes
    Commercial Relationships   Hiroki Asano, Santen Pharmaceutical Co., Ltd. (F); Tomohiro Ogami, Santen Pharmaceutical Co., Ltd. (F); Aya Iguchi, Santen Pharmaceutical Co., Ltd. (F); Maki Sano, Santen Pharmaceutical Co., Ltd. (F); Yoshiaki Yamada, Santen Pharmaceutical Co., Ltd. (E); Takahiro Hiraoka, Santen Pharmaceutical Co., Ltd. (R); Tetsuro Oshika, Santen Pharmaceutical Co., Ltd. (F), Santen Pharmaceutical Co., Ltd. (C), Santen Pharmaceutical Co., Ltd. (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1788. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hiroki Asano, Tomohiro Ogami, Aya Iguchi, Maki Sano, Yoshiaki Yamada, Takahiro Hiraoka, Tetsuro Oshika; Efficacy and safety of diquafosol ophthalmic solution for soft contact lens-related dry eye. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1788.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy and safety of 3% diquafosol ophthalmic solution (DQS) for soft contact lens (SCL)-related dry eye.

Methods : Twenty-eight SCL wearers with dry eye symptoms and ocular findings from 65 Japanese SCL wearers were enrolled into this study. DQS was applied to the right eye and artificial tears (AT) to the left eye over SCL 6 times per day for 4–8 weeks. At Baseline, at week 4 and 8 after instillation, visual acuity, contrast sensitivity by CSV-1000, fluorescein tear film break-up time (fBUT), corneal fluorescein and conjunctival lissamine green staining score, and the modified “contact lens dry eye questionnaire” were assessed. The results were compared within each group, and between the two groups. SCL parameters that include lens diameter, base curve, and light transmission rate were measured for 2-week SCL users after 2 weeks of the instillation in contact lens institute, Menicon Co., Ltd.

Results : Twenty-six subjects (1-day SCL wearers: n=14, 2-week: n=12), average 37.6 ± 9.6 years old, completed the 4-weeks examinations, and nineteen subjects completed the 8-weeks examinations. Visual activity showed no changes in both groups. In the DQS group, contrast sensitivity improved significantly (p<0.05) and was better (p<0.05) at 12 cycle/degree than in the AT group. The fBUT tended to extend after instillations in both groups although there were no significant differences. The corneal and conjunctival staining score decreased significantly in the DQS group (p<0.05, p<0.001). The conjunctival staining score was significantly better in the DQS groups (p<0.05) than in the AT group. The score of ocular symptom such as tired eye, redness, epiphora, closing eyes for relief, foreign body sensation, and photophobia significantly improved in both groups (p<0.05). In the DQS group, dryness and blurred vision significantly improved (p<0.01). In the AT group, soreness and itching significantly improved (p<0.05). SCL fitting was appropriate throughout the study period in all eyes. There were no apparent differences in the lens diameter, base curve, and light transmission rate between the collected SCLs from the DQS and AT groups. In addition, no serious adverse events were observed in all eyes throughout the study period.

Conclusions : The DQS can be used safely for SCL-related dry eyes. The DQS can improve contrast sensitivity, ocular surface staining, and subjective symptoms in SCL wearers.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×